bedaquiline and Malnutrition

India accounts for a quarter of the world's multidrug-resistant tuberculosis (MDR-TB); with less than 50% having successful treatment outcomes. Bedaquiline (BDQ) was approved for use under conditional access program in India in 2015.. We evaluate the effectiveness, safety, and tolerability of a BDQ containing regimen used under field settings in India.. Interim analysis of a prospective cohort of MDR-TB patients on a BDQ containing regimen at six sites in the country.. Six hundred and twenty MDR-TB patients [349 (56%) males; 554 (89%) between 18 and 50 years and 240 (39%) severely malnourished] were started on BDQ containing regimen between June 2016 and August 2017. There 354 (57%) patients had MDR-TB with additional drug resistance to fluoroquinolone (MDR. BDQ with a background regimen has the potential to achieve higher and faster culture conversion rates with a lower toxicity profile among DR-TB patients. Use of BDQ with additional monitoring may be safe and effective even in the field settings.

Topics: Adolescent; Adult; Antitubercular Agents; Compassionate Use Trials; Culture Techniques; Diarylquinolines; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; India; Long QT Syndrome; Male; Malnutrition; Middle Aged; Pharmacovigilance; Proportional Hazards Models; Prospective Studies; Sputum; Thinness; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Young Adult